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Abstract
Perianal fistulas are still a major challenge in everyday clinical practice. 
Particularly difficult fistulas, like those in Crohn’s Disease, often require 
multiple aggressive surgical interventions, with high risk of sphincter damage 
and incontinence. Intensive trials have been conducted for over 10 years on the 
treatment of difficult fistulas with mesenchymal stem cells (MSC). This paper 
presents a short review of basic mechanisms of mesenchymal stem cells in healing 
of damaged tissues and results of major clinical trials. MSC in perianal fistulas, 
regardless of research protocol has a 70% healing rate in recurrent fistulas and 
in fistulas in Crohn’s Disease. Further research is needed to precisely define the 
indications for MSC-based treatment of tissue damage, and particularly perianal 
and recto-vaginal fistulas. 
Keywords: Fistula-in-ano; Recurrent fistula; Complex fistula; Crohn disease; 
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Abbreviations: ASC: Adipose-derived mesenchymal Stem Cells: 
MSC isolated from adipose tissue; bFGF: Basic Fibroblast Growth 
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Factor; ILGF-1: Insulin-Like Growth Factor 1; VEGF: Vascular-
Endothelial Growth Factor
Introduction
Perianal and rectovaginal fistulas are pathological connections 
between the rectum and adjacent structures in the rectoanal 
region. About 80% of perianal fistulas are of cryptoglandular 
origin the remaining 20% develop in Crohn’s Disease, after 
trauma, or have iatrogenic etiology, etc. 
Standard in perianal fistula treatment are cutting (fistulotomy, 
fistulectomy) or non-cutting (seton) surgical procedures, to 
remove granulation tissue, necrosis and translocated mucosal 
cells. The success rate of primary surgical treatment of perianal 
fistulas reaches about 70% [1]. In the remaining cases, there is no 
healing of the fistula after the procedure, or the fistula reoccurs 
after initial healing. Fistula recurrence rate in Crohn’s Disease is 
relatively high (34%) [2] which is due to constant inflammation 
of the intestines and soft tissues. Therefore surgical approach is 
preceded by immunosuppressive treatment, including anti-TNFα, 
which is necessary for proper soft tissues healing. 
Regardless of the fistula etiology, the disease greatly 
reduces the patients’ quality of life both due to recurrence and 
incontinence [3]. The metaanalysis by Blumetti et al. [4] shows, 
that aggressive surgical approach (eg. fistulectomy) has a greater 
chance of successful healing, at the same time increasing the risk 
of fecal incontinence. Therefore, there is a constant search for 
better alternatives for fistula treatment. 
In 2003 Prof. Garcia-Olmo made the first attempt to treat a 
rectovaginal fistula in a 33-year old female patient with Crohn’s 
Disease, using the mesenchymal stem cells derived from the fatty 
tissue of the patient (Adipose-derived mesenchymal Stem Cells) 
[5]. By implantation of about 9mln of autologous stem cells he 
achieved complete closure and lack of recurrence of the fistula. 
From that time, many approaches to soft tissue treatment with 
MSC were made. This paper presents a short review of clinical 
research on the MSC treatment of perianal and rectovaginal 
fistulas so far. 
Discussion
Mechanism of action
Mesenchymal stem cells exist in the perivascular niche of 
almost all tissues [6], however, the most useful source of these 
cells are bone marrow, adipose tissue and umbilical cord [7]. 
In classic approach, MSC are pluripotent cells that support the 
natural healing process by increasing the overall pool of cells (self-
renew) and differentiation in the direction of mesenchymal cells 
(fibroblasts producing collagen, adipocytes, myocytes, osteocytes, 
etc.) [8]. In addition, MSC modulate the healing process by 
stimulating dermal fibroblasts to divide, migrate toward the 
injury, and the expression of collagens [9]. In hypoxic conditions 
which occur on the edges of tissue damage, MSC secrete growth 
factors, such as vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), 
insulin-like growth factor, and other [10] therefore inducing 
revascularisation [11]. Mesenchymal stem cells also possess 
immunosuppressive properties [12,13]. In a mouse model of 
inflammatory bowel disease MSC suppress Th1 lymphocytes, 
which leads to a reduction in clinical and histological symptoms 
of inflammatory bowel disease [13]. Multifactorial mechanism 
of action of MSC responds to the need for proper healing of soft 
tissue, but we still do not know which of the effects described by 
basic science have clinical significance. What’s more, there are no 
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direct studies on the characteristic of the microenvironment of 
the damaged tissue, and in particular its “weak spots” in relation 
to the properties of the MSC, which could allow the development 
of better treatment strategies.
Clinical outputs
Since 2005 at least 9 clinical trials with MSC treatment of 
the perianal fistula were conducted [14-24]. The summary of 
prospective studies are shown in Table 1. In all studies, 225 cell-
treated patients were completed the protocol, 107 were healed 
in 8-24 weeks of follow-up.In all trial administration of the cells 
was combined with surgical closure of the fistula (one-stage 
procedure). Patients received 9 to 139 million cells suspended in 
fibrin glue [15,16,23] or in saline solution [15,19-22]. The cells 
were administered into the walls of the fistula and into its lumen. 
Table 1: Summary of clinical trials and compassionate-use programmes with mesenchymal stem cells therapy in treatment of fistulas.
Published Clinical Trial Etiology of Fistula Type and Amount of Cells N / n H / h
1 Garcia-Olmo et al. [14] Crohn Autogenic ASC, 3-30 mln 9 6
2 Garcia-Olmo et al. [23] both Autogenic ASC, 20 mln 17/ 7* 12/ 5*
3 Ciccocioppo et al. [18] Crohn Autogenic MSC, 54-139 mln 10 7
4 de la Portilla et al. [20] Crohn Allogenic ASC, 20-40 mln 16 9
5 Herreros et al. [15] non-Crohn Autogenic ASC, 20 mln 124 51
Results in multicenter trial excluded a 
pioneering center 101 35
Results in the pioneering center (Garcia-
Olmo) 23 16
6 Lee et al. [16] Crohn Autogenic ASC, 9-42 mln 33 27
7 Cho et al. [17] Crohn Autogenic ASC, 30-40 mln 9 3
8 Garcia-Olmo et al. [22]** Both Auto- autogenic ASC, no data 7 / 3* 4 / 2*
9 Garcia-Arranz et al. [24] Crohn Allogenic ASC, 20-40 mln 5 3
N: number of cell-treated patients who completed the protocol, H – number of cell-treated patients with healed fistula in 8-24 weeks follow-up; * - 
Number of non-Crohn/Crohn patients; ** - Compassionate-use programme.
It is difficult to determine the efficacy of MSC / ASC as each of 
these studies had a slightly different protocol. For this reason, the 
total numbers of patients were counted - patients who received 
mesenchymal stem cells (isolated from bone marrow and 
adipose tissue, auto and allogeneic, alone or with fibrin glue) in 
clinical trials or registered treatment programs (compassionate 
use). Only prospective studies were taken into account, and the 
endpoint (ie. “healed”) was considered as clinical healing in the 
period from 8 to 24 weeks after administration of the cells (the 
status of “partially healed” was classified as “not healed” unless 
the healing was achieved up to 12 months after the cells were 
administered).
Among 225 (or 154) patients who received the MSC or ASC 
status of “healed” were reported in 138 (54%) (or 103 (67%) 
- excluding non-pioneering center form the largest clinical trial 
conducted by Herreros et al. [15]) cases. The healing rate in non-
Crohn fistulas were 45% (n=148 cell-treated patients) and (or 
68% (n=47) excluding non-pioneering centers from Herreros et 
al.). We decided to separately present a results from Herreros 
et al. because of only in the pioneering center outcomes of cell-
treatment patients were significantly better than in the rest 
centers (the healing rate in 19 centers were 50% (n=124) but in 
pioneering center reached 70% (n=23)). This fact suggest major 
influence of experience in cell-based products management on 
the final results. 
In the case of Crohn’s Disease overall healing rate was 66% 
(n=107) which include Lee et al. [16] where reported healing 
rates even up to 82%. There are several different strategies 
reported in the literature (use of auto or allogenic cells, the 
administration of from 9 to 139 million cells, the administration 
of cells in fibrin glue, or alone, administration of cells at once or 
sequentially until healed, and various ways to provide the fistula 
before administration of the cells). Therefore it is very difficult to 
compare results between studies. However, achieved results show, 
that there is a positive effect of the MSC on soft tissue healing. 
In the presented studies some of AE (adverse effects) were 
reported but only in Herreros et al. [15] there were reporting in 
systematic condition. The most frequent adverse effects [15] were 
a proctalgia (43%) (that was also reported by our team (data not 
shown)) and abscess drainage (22.4%). Pain, perianal abscess, 
pyrexia, swelling and pruritus were also reported in around 10% 
Citation: Walega P, Piejko M, Romaniszyn M, Drukala J  (2016) Mesenchymal Stem Cells in Treatment of Perianal and Rectovaginal Fistulas. 
Gastroenterol Hepatol Open Access 5(4): 00149. DOI: 10.15406/ghoa.2016.05.00149
Mesenchymal Stem Cells in Treatment of Perianal and Rectovaginal Fistulas 3/4
Copyright:
©2016 Walega et al.
or less patients who were included in protocol [15]. Frequency 
of these effects were no statistically differences within groups 
which received the cells or fibrin glue. In longer observation the 
most probability AE, directly associated with cell transplantation 
- uncontrolled cellular growth were no reported in Herreros et al. 
and another publication as well.
Lack of differences between groups in occurring of the AE and 
lack of the uncontrolled cellular growth suggest that reported 
adverse effects were more related to the act of administration an 
ascetical products risky perianal location than the products were a 
mesenchymal stem cells. It must be stressed here that cells cannot 
be sterilized as typical pharmaceutics (ex. gamma sterilization) 
even more a precise bacteriological status of cell-living product 
is unknown at the time of cells administration (all methods of 
microbiological assessment have to be incubated at least a couple 
of hours to observe a pre-result; but an aseptic examination that 
have to be conduct to precise assess of the final product require a 2 
weeks of incubation (accordingly with European Pharmacopeia). 
From that reasons using of cell-living products demand a high 
quality of cell production in cell banks, trained medical staff as 
well as perfect coordination between themselves.
Conclusion
In clinical trials so far, the healing rates of MSC fistula 
treatment was about 70%. Pleiotropic effect of action of the stem 
cells seems to be particularly beneficial in the process of perianal 
fistula healing, but we still don’t know, whether the cells are 
permanently built into the tissue, and what clinical value have 
the properties of the cells we described. From that reason there is 
still grate necessity to explore a mechanism of soft tissue healing 
driven by autogenic as well as allogenic MSC. Developing of spin-
labelling technics and magnetic resonance imagining seems to be 
useful tools in investigation of “fate of cells” after implantation 
and can be directly implemented in clinical trials protocols. The 
explanation of these aspects will help to develop better strategies 
to introduce the cells and thus contribute to the definition of 
precise indications for such treatment. 
The cell-based therapies that are still in investigational 
phase require from all scientific and medical society to treat the 
patients only in restricted conditions of registered clinical trials 
or compassionate use programs to decrease chance of serious 
adverse effects. In over 10-year long research on safety and 
effectiveness of the mesenchymal stem cells in treatment of soft 
tissues give hope for a new, safer therapeutic option, especially 
useful in difficult fistula cases but still need more effort to better 
understand a nature and consequences of cell-based products.
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